From our partners at Paradigm Press Below is an important message from one of our highly valued sponsors. Please read it carefully as they have some special information to share with you.
Dear Reader,
As co-host of The Clay Travis & Buck Sexton Show… one of the most listened-to radio programs in the country… I’ve conducted a lot of important interviews over the years…
But I’ve never done anything like this.
Take a look.
As you’re about to hear… there’s a rapidly developing and massively critical situation quickly unfolding in the Trump Administration right now…
The mainstream media – and very few Americans know anything about this.
But what I believe Trump has up his sleeve could flood an estimated $2.2 trillion into a handful of little-known technology companies over the next decade…
And potentially spark a 40-year economic boom that reshapes this country from the ground up.
I believe this will make history.
I wouldn’t be doing my job if I didn’t come forward and explain what’s happening.
This may be the most important message I’ve ever shared.
Please take a moment to watch my interview now.
You’ll be so glad you did.
Buck Sexton
Former CIA Officer and Co-Host, The Clay & Buck Show
Special Report 2 Small-Cap Biotechs That Could Reward Patient InvestorsWritten by Chris Markoch. Article Posted: 12/12/2025. 
In Brief - Small-cap biotech stocks like Mainz Biomed and NanoViricides offer high risk but the potential for outsized returns as their diagnostic and antiviral pipelines advance.
- Mainz Biomed’s ColoAlert test provides early commercial traction, but limited revenue and ongoing cash needs continue to pressure MYNZ stock.
- NanoViricides’ nanomedicine antiviral platform shows promising preclinical data, yet NNVC remains a speculative bet dependent on new funding and pipeline progress.
Speculative investors and patience rarely go together. Nevertheless, if you’re considering the small-cap biotech sector, patience is a requirement. Most of these companies remain in the clinical stage and do not yet have commercially available drugs or therapeutics. That status typically means negative earnings (i.e., they are not profitable) and little to no revenue. Success often hinges on the outcome of a single clinical-stage candidate. Elon Musk's Starlink project is generating major speculation ahead of a potential IPO that some analysts believe could reach a historic $100 billion valuation. According to James Altucher, there may be a smart "backdoor" way for everyday investors to position ahead of that event without needing traditional IPO access — and he says it can be done for under $100. He's also sharing a free ticker tied to this trend for anyone who wants to take a closer look. Click here to learn more Even if a product advances through trials, profitability can still be years away. Only after reaching that milestone do companies typically attract the analyst coverage that brings institutional investment. However, getting in on one of these medical stocks and seeing it succeed can produce lottery-like returns. Investors could realize 3x, 5x, or even 10x gains in a short period. Many other companies—of course—may never pan out. It’s why some investors who follow penny stocks spread a lump sum across many biotech names. If it is a numbers game, diversification can be an effective strategy. With that in mind, here are two small-cap biotech stocks that carry significant risk but offer the potential for outsized returns. Mainz Biomed: Early Cancer Detection With High Upside Potential Mainz Biomed AG (NASDAQ: MYNZ) is a German molecular diagnostics company focused on epigenetics-based tests for early cancer detection. Unlike many penny-stock biotechs, Mainz Biomed already has a commercially available product: ColoAlert—the first DNA-based screening tool for colorectal cancer in Europe. On Dec. 2, Mainz Biomed announced that ColoAlert was added to the portfolio of DoctorBox, a leading German digital health pioneer. With over 60,000 new colorectal cancer cases annually in Germany, the market opportunity is meaningful. The company is also in the early stages of developing a non-invasive, blood-based screening test for early detection of pancreatic cancer. Mainz Biomed reported positive topline results in October, but commercial approval is still years away. The risks remain substantial. ColoAlert is not yet available in the United States, and despite initial sales in Europe and expansion plans for South America, revenue today is minimal. Reflecting that reality, the company included “going concern” language in its Sept. 26 SEC filing, indicating uncertainty about its ability to continue without additional financing. Since then, Mainz Biomed has filed a $150 million mixed shelf offering. For now, that capital access helps keep the MYNZ stock price above $1 and avoids a delisting notice. The company must generate substantially more revenue to change its financial profile. If it succeeds, however, even a relatively small investment could produce substantial returns. NanoViricides: High-Risk Antiviral Play With Breakthrough Potential NanoViricides Inc. (NYSE: NNVC) is another micro-cap biotech pursuing a potentially disruptive antiviral approach—yet it also carries the financial risks typical of speculative drug developers. NanoViricides is developing a novel class of antiviral therapies based on its proprietary “nanoviricide” platform. These candidates are designed to mimic human cell surfaces and lure viruses into binding with them, neutralizing the pathogens before they can infect real cells. It’s an innovative concept that, if validated in human trials, could represent a new method for treating infectious diseases. The company’s pipeline includes candidates targeting shingles (varicella-zoster virus), HSV-1 and HSV-2, and broad-spectrum influenza. Its shingles program, NV-HSC, is the most advanced and has shown encouraging preclinical antiviral activity. Like many micro-cap biotechs, NanoViricides remains pre-revenue and reliant on additional capital to advance its programs. Recent filings show limited cash on hand, and investors should expect the possibility of future dilution. Still, if even one candidate advances successfully into clinical development, the valuation upside could be substantial. For investors with patience and a high tolerance for risk, NNVC represents a genuine moonshot in the antiviral space.
| 
